Gilead Sciences CDR (GILD.CA) Stock Price & Overview
TSX:GILD
Current stock price
The current stock price of GILD.CA is 28.19 CAD. Today GILD.CA is up by 0.04%. In the past month the price decreased by -5.31%.
GILD.CA Key Statistics
- Market Cap
- 34.99B
- P/E
- 2.52
- Fwd P/E
- 2.32
- EPS (TTM)
- 11.19
- Dividend Yield
- 2.31%
GILD.CA Stock Performance
GILD.CA Stock Chart
GILD.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GILD.CA.
GILD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to GILD.CA. GILD.CA gets an excellent profitability rating and is at the same time showing great financial health properties.
GILD.CA Earnings
On February 10, 2026 GILD.CA reported an EPS of 1.86 and a revenue of 7.92B. The company beat EPS expectations (0.73% surprise) and beat revenue expectations (0.98% surprise).
GILD.CA Forecast & Estimates
39 analysts have analysed GILD.CA and the average price target is 32.26 CAD. This implies a price increase of 14.44% is expected in the next year compared to the current price of 28.19.
For the next year, analysts expect an EPS growth of 8.48% and a revenue growth 3.43% for GILD.CA
GILD.CA Groups
Sector & Classification
GILD.CA Financial Highlights
Over the last trailing twelve months GILD.CA reported a non-GAAP Earnings per Share(EPS) of 11.19. The EPS increased by 76.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.9% | ||
| ROA | 14.42% | ||
| ROE | 37.49% | ||
| Debt/Equity | 0.97 |
GILD.CA Ownership
GILD.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 593.929M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 403.733M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.73 | 54.688M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 50.052M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 42.848M | ||
| RVX | RESVERLOGIX CORP | N/A | 34.751M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.39 | 33.18M | ||
| MPH | MEDICURE INC | N/A | 14.094M | ||
| HEM | HEMOSTEMIX INC | N/A | 12.691M | ||
| CSCI | COSCIENS BIOPHARMA INC | N/A | 8.65M | ||
| KNE | KANE BIOTECH INC | N/A | 6.365M | ||
| TELO | TELO GENOMICS CORP | N/A | 6.026M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About GILD.CA
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
Company Info
IPO: 1992-01-22
Gilead Sciences CDR
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17000
Phone: 13026587581
Gilead Sciences CDR / GILD.CA FAQ
What does Gilead Sciences CDR do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
What is the current price of GILD stock?
The current stock price of GILD.CA is 28.19 CAD. The price increased by 0.04% in the last trading session.
Does GILD stock pay dividends?
Gilead Sciences CDR (GILD.CA) has a dividend yield of 2.31%. The yearly dividend amount is currently 4.45.
What is the ChartMill technical and fundamental rating of GILD stock?
GILD.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is Gilead Sciences CDR worth?
Gilead Sciences CDR (GILD.CA) has a market capitalization of 34.99B CAD. This makes GILD.CA a Large Cap stock.
Can you provide the ownership details for GILD stock?
You can find the ownership structure of Gilead Sciences CDR (GILD.CA) on the Ownership tab.